A growth factor that is mitogenic for vascular endothelial cells, with an ED50 of~'1 ng/ml, has been purified 170,000-fold to apparent homogeneity from tissue culture medium conditioned by a rat glioma-derived cell line. The pure protein is a 46-kDa dimer composed of two subunits of equivalent mass as established by comparison of migration in SDS/polyacrylamide gels with and without prior reduction.
growth factors and to platelet-derived endothelial cell growth factor, which have no secretory leader sequences and might only be released by leakage from damaged cells, the glycoprotein nature of this mitogen implies that it is processed through the glycosylating secretory pathway. This secretable growth factor could, therefore, be readily available in the extracellular space under normal physiological conditions in vivo to promote vascular endothelial cell proliferation associated with bloodvessel growth and maintenance.
Vascular endothelial cells grow as a nonthrombogenic monolayer lining the interior surface of the blood vessels throughout the body. Capillaries are simple tubes of these cells surrounded by a basement membrane, whereas the endothelium of large vessels is surrounded in addition by one or more layers of smooth muscle. Following early embryogenesis, new blood vessel formation (angiogenesis) proceeds by the sprouting of capillaries from the microvasculature. Sustained angiogenesis and, presumably, extensive large-vessel repair depend on mitosis of vascular endothelial cells.
In recent years several vascular endothelial cell growth factors have been identified. The first such factors to be thoroughly characterized comprise a family of proteins related by amino acid sequence homology, the 15-to 30-kDa heparin-binding fibroblast growth factors (FGFs). This family includes acidic FGF (aFGF), basic FGF (bFGF), and the protein products of the int-2, hst/KS3, genes (1-7). All of these FGFs, with the exception of the int-2 and FGF-6 gene products, which have not been isolated, have been shown to be potent vascular endothelial cell mitogens in vitro. Furthermore, exogenously applied aFGF (8) and bFGF (9) induce angiogenesis in vivo. An angiogenic platelet-derived endothelial cell growth factor (PD-ECGF), a monomeric 45-kDa protein, has also been purified and structurally characterized. This protein, like aFGF and bFGF, lacks a secretory leader sequence and so is presumably released by lysis of platelets (10, 11) . Finally, both granulocyte-and granulocyte/macrophage-colony-stimulating factors, monomeric hematopoietic growth factors of 18.6 and 19.5 kDa respectively, stimulate proliferation of vascular endothelial cells in vitro and, perhaps, in the hematopoietic microenvironment (12) . Vascular endothelial cells, therefore, appear to be able to respond to multiple mitogenic signals, indicating that they are under potentially complex growth regulation in vivo.
We have identified and purified a vascular endothelial cell mitogen that is not only produced but also apparently secreted by cultured cells derived from a chemically induced rat glioma (13) . This glioma-derived vascular endothelial cell growth factor (GD-VEGF) is structurally unrelated to the previously well-characterized mitogens for large-vessel endothelium. Pure GD-VEGF approaches the specific mitogenic activity of FGFs for cultured human umbilical vein endothelial (HUVE) cells.
MATERIALS AND METHODS
Mitogenic Assays. HUVE cells were isolated and maintained as described (14) . The 
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grown until approximately one population doubling from confluence. The medium was then removed, the factory was washed three times with phosphate-buffered saline, and 1.5 liters of serum-free medium supplemented with insulin (20 Ag/ml; Sigma), transferrin (10 Ag/ml, Sigma) and lx traceelement mix (GIBCO). The conditioned medium was collected and replaced by fresh serum-free medium after 24 hr and, subsequently, at 48-hr intervals for up to 1 week. Conditioned medium was filtered to remove loose cells and stored frozen at -200C.
Purification of GD-VEGF. Thawed serum-free GS-9L conditioned medium was brought to pH 6.0 with 1 M HCO and 1.5 g of sterile, preswollen CM-Sephadex C-50 cation-exchange resin (Pharmacia) was added per 6 liters of medium. The mixture was stirred overnight at 40C and the resin was collected, packed into a column, and washed with 50 mM sodium phosphate, pH 6.0/0.1 M NaCl until the A280 of the eluate decreased to 0.05. Bound GD-VEGF activity was eluted at 40C from the C-50 column by addition of sodium phosphate buffer containing 0.5 M NaCl. The C-50 eluate was subsequently loaded onto a column containing 5 ml of Con A-agarose (Vector Laboratories) that had been preequilibrated at 40C in 50 mM NaOAc, pH 6.0/0.5 M NaCl/1 mM CaCl2/1 mM MnCl2. After the C-50 eluate was loaded, the Con A-agarose was washed with the NaOAc equilibration buffer and bound proteins were eluted with the same buffer adjusted to 0.15 M NaCl and 0.5 M methyl a-D-mannoside. After elution with 45 ml, the flow was stopped for 1 hr and then restarted to minimize tailing of the activity peak that presumably resulted from slow dissociation of a portion of the glycosylated mitogen from the lectin column. This eluate was loaded directly onto a 0.46 x 25 cm poly(aspartic acid) WCX HPLC column (Nest Group) that had been preequilibrated in 50 mM sodium phosphate (pH 6.0) at 20-22°C. Bound proteins were eluted from the column by a 30-min linear gradient of 0-0.75 M NaCl in equilibration buffer at a flow rate of 0.75 ml/min. Eluate fractions comprising the second major peak of mitogenic activity were loaded onto a 0.46 x 5.0 cm Vydac C4 reversed-phase HPLC column (The Separations Group) equilibrated in 0.1% trifluoroacetic acid. GD-VEGF was eluted from the column by a 60-min linear gradient of 0-67% acetonitrile in 0.1% trifluoroacetic acid at a flow rate of 0.75 ml/min. Polypropylene tubes containing 150 ,l4 of 1 M Hepes buffer (pH 7.55) were used to collect and neutralize the 750-,ul fractions. Polyacrylamide Gel Electrophoresis. The molecular masses of pure GD-VEGF, with or without prior reduction of disulfide bonds by dithiothreitol, were determined by SDS/12.5% PAGE (15) . Pure unreduced mitogen was also analyzed by SDS/12.5% PAGE after alkylation for 2 hr at 20-22°C with S mg of iodoacetamide (Sigma) in 20 ,u of 10 mM Tris buffer (pH 8.1). Gels were glutaraldehyde-fixed and silver-stained (1) . Unalkylated and unreduced GD-VEGF was also electrophoresed through a 3-mm-thick x 11-cm-long SDS/12.5% polyacrylamide slab gel. The gel was sliced into 1-cm pieces that were each crushed and extracted overnight at 4°C into 1 ml of phosphate-buffered saline. Samples were passed through sterile, 0.22-,um-pore Millex-GV syringe filters (Millipore) to remove gel fragments, concentrated in Centricon-10 filter centrifuge tubes (Amicon), and assayed for mitogenic activity.
Amino Acid Analysis. Pure protein was reduced with dithiothreitol, carboxymethylated with iodoacetic acid containing iodo [2-14C] Mitogens for HUVE cells bound to CM-Sephadex C-50 and were eluted at pH 6.0 with 0.5 M NaCl (Fig. lA) . A substantial fraction of this mitogenic activity bound to a Con A lectin affinity column and was specifically eluted with methyl a-D-mannoside (Fig. 1B) . The binding to Con A indicates that mitogenic activity is attributable to a glycoprotein. Three peaks of mitogenic activity were partially resolved, the last one of which is an artifact of stopping the flow for 1 hr following 45 ml of elution to minimize tailing. The first two peaks, however, represent heterogeneity of binding to Con A that could reflect different glycosylation patterns either on the same or on different endothelial cell mitogens. The fractions of low specific mitogenic activity that fail to exhibit affinity for Con A contain high-affinity heparin-binding growth factors that will require structural characterization to determine their relationship to the known FGFs. The Con A-binding mitogenic activity was pooled and further fractionated by cation-exchange HPLC on a poly(aspartic acid) WCX column (Fig. 1C) . Again, the activity was clearly resolved into two species by elution from this column at pH 6.0 with a linear gradient of NaCl. The second major peak of activity occurred in a region of relatively low protein concentration and because of its higher specific mitogenic activity was chosen for subsequent purification. Protein in this peak was pooled and purified to apparent homogeneity by elution with a linear gradient of acetonitrile from a C4 reversed-phase HPLC column equilibrated in 0.1% trifluoroacetic acid (Fig. 1D) .
The purification of GD-VEGF is summarized in Table 1 . A purification of 170,000-fold was achieved with a 5% recovery of activity. This is probably an underestimate of the fold purification and percent GD-VEGF recovered from conditioned medium, since other endothelial cell mitogenic activities were removed by the purification. The Mitogenic activity for HUVE cells was monitored throughout the purification. Active eluate fractions pooled either for subsequent purification or for characterization are noted by horizontal bars. (A) CM-Sephadex C-50 chromatography. Filtered serum-free conditioned medium (6 liters) from GS-9L cells was adjusted to pH 6.0, stirred with 1.5 g of preswollen CM-Sephadex C-50 at 40C, and packed into a 1.4-cm-diameter column. The resin was rinsed with 0.1 M NaCI in 50 mM sodium phosphate buffer (pH 6.0), and bound material was eluted with the same buffer containing 0.5 M NaCI. (B) Con A lectin affinity chromatography. The mitogenically active eluate from the C-50 column was applied to a 0.9-cm-diameter column containing 5 ml of Con A-agarose equilibrated at 40C with 50 mM NaOAc, pH 6.0/0.5 M NaCI/1 mM CaCI2/1 mM MnCI2. After unbound material was rinsed from the column, specifically retained proteins were eluted with the same buffer adjusted to 0.15 M NaCl and supplemented with 0.5 M methyl a-D-mannoside. (C) Poly(aspartic acid) WCX cation-exchange HPLC. The mitogenically active eluate from Con A-agarose was directly loaded onto a 0.46 x 25 cm poly(aspartic acid) WCX column equilibrated in 50 mM sodium phosphate (pH 6.0) at 20-220C and was eluted with a linear gradient of NaCl. (D) C4 reversed-phase HPLC. The second major peak of mitogenic activity from the previous column was loaded onto a 0.46 x 5.0-cm Vydac C4 column equilibrated in 0.1% trifluoroacetic acid and was eluted with a linear gradient of acetonitrile at 20-220C. The symmetrical peak of active GD-VEGF was pooled for further characterization of purity, structure, and activity. determining accurate masses by SDS/PAGE under nonreducing conditions. Highly disulfide-crosslinked proteins can be hydrodynamically more compact and bind less SDS than the reduced proteins used as molecular mass standards and, therefore, can exhibit anomalous electrophoretic migration.
Unreduced protein standards were run in SDS/PAGE along with reduced protein standards for comparison of alterations in relative mobilities after reduction.
Mitogenic activity was extractable from the 50-kDa mass region of SDS/polyacrylamide gels after electrophoresis of Gel Slice unalkylated and unreduced GD-VEGF (Fig. 2B) , which is consistent with the mass estimate of the active partially purified mitogen determined by gel filtration (data not shown). In contrast, no activity could be recovered by elution ofthe reduced protein from SDS gels, indicating that disulfide bonds are required for not only dimerization but also activity. The amino acid composition of pure GD-VEGF (Table 2 ) was determined for the unreduced dimer and following reduction, carboxymethylation, and repurification of the protein. N-Acetylglucosamine was clearly identified in this analysis, an observation compatible with the binding of the mitogen to Con A-agarose. A preliminary estimate of the amount of carbohydrate can be determined from the decrease in subunit mass from 23 to 20 kDa after treatment with endoglycosidase H as determined by reducing SDS/PAGE (data not shown). This 20-kDa deglycosylated polypeptide subunit mass was used as the basis for scaling the amino acid composition of the dimer to 40 kDa.
Purified GD-VEGF is a potent mitogen for large-vessel endothelial cells, half-maximally stimulating HUVE cell DNA synthesis at -1 ng/ml (Fig. 3) . The addition of 10-100 ,ug of heparin per ml of assay medium, levels that potentiate from reduced standards electrophoresed in the same gel and silver-stained.
the activity of aFGF on these cells, had no effect on their response to GD-VEGF. In contrast, the pure mitogen was inactive in a concurrent assay on BALB/c 3T3 fibroblasts (Fig. 3) simply a proteolytically clipped product of the monomeric PD-ECGF, since the amino acid compositions of the two proteins clearly differ, particularly with respect to cysteine content, which is -4 times greater in GD-VEGF (11) . Furthermore, like aFGF and bFGF, PD-ECGF does not have a recognizable secretory leader sequence and apparently does not become glycosylated since it is not exposed to the glycosyltransferases along the secretory pathway. In addition, PD-ECGF has no affinity for the sulfated glycosaminoglycan heparin, whereas GD-VEGF has moderate affinity for heparin-Sepharose, from which it can be eluted with 0.6 M NaCI (unpublished data). Finally, an undetected trace contaminant of PD-ECGF cannot account for the mitogenic activity of GD-VEGF. The putative contaminant would have to be less than 1-2% of the total protein to escape detection in the silver-stained reduced electrophoretic gels. At this abundance, PD-ECGF would need to have an ED50 of 10-20 pg/ml to account for the observed mitogenic activity of GD-VEGF, compared to the ED50 of 20 ng/ml reported for pure PD-ECGF on porcine aortic endothelial cells (10) . Taken together, these data clearly indicate that GD-VEGF is not one of the previously characterized endothelial cell mitogens. Following completion of this work, the identification and partial characterization of a vascular endothelial cell growth factor (VEGF) isolated from nontransformed bovine pituitary follicular cell conditioned medium was reported (19) . Like PD-ECGF and GD-VEGF, VEGF has a target-cell specificity that is apparently more restricted to vascular endothelial cells than that observed for the FGFs. The specific mitogenic activity reported for VEGF on adrenal cortex-derived capillary endothelial cells is comparable to that we observe for GD-VEGF on HUVE cells. VEGF is also a dimer whose subunit size is -23 kDa, similar to that of GD-VEGF. A direct comparison of either polypeptide subunit masses or amino acid compositions is not currently possible since neither demonstration of the extent of glycosylation, if any, nor amino acid composition was reported for pituitary cell-derived VEGF. Moreover, based on the current level of characterization, we cannot yet determine if these mitogens are either equivalent proteins from different species, or unique members of a family of homologous protein growth factors, or merely fortuitously similar.
The established target-cell specificities and potential modes of delivery of the polypeptide mitogens identified to date raises questions concerning their physiological signifcance in vascular development. Not only aFGF and bFGF, but also probably other members of the FGF family, are broad-spectrum mitogens that induce division in most, if not all, cells of mesodermal and ectodermal embryonic origin. FGFs might, therefore, function as general regulators of cellular growth rather than as specific angiogenic stimuli. Both aFGF and bFGF might not be secreted from normal healthy cells since their mRNAs do not code for recognizable secretory leader sequences. Induction of blood-vessel growth by these FGFs could, therefore, be restricted to their passive release by cell lysis as a result of conditions such as programmed cell death during embryonic development and damage associated with tissue injury. Similarly, PD-ECGF, which also has no secretory leader sequence, might be released by lysis of platelets at sites of vascular damage to provide a signal for regeneration of the endothelial vessel lining.
In contrast, glycosylated secretory proteins like GD-VEGF clearly have the capacity to function as intercellular signals for vascular induction and maintenance in not only pathological but also normal conditions. If, for example, the integrity of a healthy vascular endothelium is maintained by secretory endothelial cell mitogens such as GD-VEGF, then diminished expression could lead to vascular degeneration. Alternatively, overexpression of such mitogens could result in pathological neoangiogenesis such as is observed in response to the growth of many types of tumors, including gliomas.
